Meeting
2022 ASCO Annual Meeting
A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
Authors
Hyung-Don Kim
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Hyung-Don Kim , Changhoon Yoo , Min-Hee Ryu , Yoon-Koo Kang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Registration Number
NCT02712112
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11538)
DOI
10.1200/JCO.2022.40.16_suppl.11538
Abstract #
11538
Poster Bd #
443
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II trial of continuous dosing of regorafenib in patients with metastatic or recurrent gastrointestinal stromal tumors (GISTs) after failure of imatinib and sunitinib.
First Author: Yoon-Koo Kang
Poster
2020 ASCO Virtual Scientific Program
LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.
First Author: Axel Le Cesne
Poster
2019 Gastrointestinal Cancers Symposium
Safety and efficacy of dasatinib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib: A single arm, multicenters, phase 2 trial.
First Author: Jian Li
Poster
2014 ASCO Annual Meeting
Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: A report of the U.K. Managed Access Program.
First Author: Marco Maruzzo